Understand the source comparison
Peptides for Parkinson's Disease Protocol Evidence Guide: Treatment Comparison
Before initiating any peptide protocol, researchers and clinicians must evaluate mechanism alignment, administration route feasibility, and evidence strength across available compounds. Cerebrolysin BDNF/NGF mimetic; TrkB receptor activation Intravenous Meta-a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before initiating any peptide protocol, researchers and clinicians must evaluate mechanism alignment, administration route feasibility, and evidence strength across available compounds.
- Cerebrolysin
- BDNF/NGF mimetic; TrkB receptor activation
- Intravenous
- Meta-analysis of 7 RCTs (777 patients); modest UPDRS improvement
- Daily IV for 21–28 days
- Most robust clinical data but requires IV access and shows no long-term benefit post-discontinuation
- P21
- STAT3 activation; endogenous BDNF upregulation
- Subcutaneous
- Preclinical (animal models only); 40% reduction in dopaminergic loss
- Daily or twice-daily
- Strong mechanistic rationale but zero human trial data; investigational use only
- Dihexa
- HGF mimetic; synaptogenesis via c-Met receptor
- Oral or subcutaneous
- Preclinical (in vitro and animal models)
- Multiple daily doses (short half-life)
- Promising for cognitive symptoms but unproven in Parkinson's-specific trials
- Thymalin
- Immunomodulation; microglial downregulation
- Intramuscular
- Single Phase II trial (64 patients); 15% UPDRS improvement
- Every other day during loading, 2–3x/week maintenance
- Best for patients with elevated inflammatory markers; adjunctive therapy only